HC Wainwright Reiterates “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $10.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on the stock. Oppenheimer started coverage on shares of Regulus Therapeutics in a research note on Friday, August 2nd. They set an “outperform” rating and a $7.00 target price on the stock. Canaccord Genuity Group raised their price objective on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Finally, StockNews.com started coverage on shares of Regulus Therapeutics in a research note on Tuesday, April 16th. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Regulus Therapeutics Price Performance

RGLS stock remained flat at $1.48 during trading on Friday. 218,837 shares of the company were exchanged, compared to its average volume of 1,650,934. The business’s fifty day moving average is $1.95 and its 200-day moving average is $2.00. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.79. The company has a market capitalization of $96.90 million, a P/E ratio of -1.01 and a beta of 1.62.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.14). As a group, research analysts forecast that Regulus Therapeutics will post -0.59 earnings per share for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RGLS. NEA Management Company LLC purchased a new stake in shares of Regulus Therapeutics in the first quarter valued at about $18,627,000. RA Capital Management L.P. purchased a new stake in shares of Regulus Therapeutics in the first quarter valued at about $18,000,000. Vivo Capital LLC purchased a new stake in shares of Regulus Therapeutics in the first quarter valued at about $14,400,000. CVI Holdings LLC purchased a new stake in shares of Regulus Therapeutics in the first quarter valued at about $4,050,000. Finally, Vanguard Group Inc. increased its holdings in Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 453,784 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.